The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines.

På svenska

Author

Summary, in English

Glycoprotein B (gB) is a major component in several vaccines that are under development for prevention of disease by cytomegalovirus. It contains multiple determinants that are targets for neutralizing antibodies. One of them is site I of antigenic domain 2 (AD-2). The epitope, defined by short peptides, is quite conserved between different isolates. However, it is poorly immunogenic in natural infection. In this study we investigated the extent to which different vaccines, attenuated live Towne vaccine with or without priming with a canarypox virus coding for gB, or a recombinant gB vaccine adjuvanted with MF59, induced antibodies to this epitope. As in natural infection only a fraction of all subjects developed antibody responses against site I of AD-2 following vaccination. We suggest that strategies that enhance immunogenicity of this epitope will improve vaccine efficacy.

Publishing year

2007

Language

English

Pages

41-46

Publication/Series

Vaccine

Volume

26

Issue

1

Document type

Journal article

Publisher

Elsevier

Topic

  • Immunology in the medical area

Keywords

  • Viral/blood
  • Cytomegalovirus Vaccines/immunology
  • Epitope Mapping
  • Humans
  • Immunization
  • Protein Structure
  • Antibodies
  • Tertiary
  • Vaccines
  • Attenuated/immunology
  • Synthetic/immunology
  • Viral Envelope Proteins/chemistry
  • Viral Envelope Proteins/immunology

Status

Published

ISBN/ISSN/Other

  • ISSN: 1873-2518